Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma

Cancer Research

Volumn 70, Issue 15, 2010, Pages 6293-6302

  Li, Bohua ^a,b,c   Zhang, Xunming ^a   Shi, Shu ^a   Zhao, Lei ^a   Zhang, Dapeng ^a,b   Qian, Weizhu ^a,b   Zheng, Lei ^a   Gao, Jie ^a,b   Wang, Hao ^a,b,c   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center for Antibody Medicine   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; COMPARATIVE STUDY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; APOPTOSIS; CELL GROWTH PROCESSES; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LYMPHOMA, B-CELL; MICE; MICE, NUDE; MICE, SCID; TRANSFECTION;

EID: 77955401079     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0009     Document Type: Article

References (21)

1. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003;8:503-10.
2. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.
3. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56:226-43.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33. (Pubitemid 28363048)
5. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74.
6. Eisenbeis CF, Caligiuri MA, Byrd JC. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res 2003;9:5810-2.
7. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52.
8. Chan HTC, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480-9. (Pubitemid 37139867)
9. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800.
10. Davis T, Kamiski M, Leonard J, Gregory S. Results of a randomized study of Bexxar (Tositumomab and I 131 Tositumomab) vs unlabeled Tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma [abstract]. Blood 2001;98:843.
11. Wolff EA, Schreiber GJ, Cosand WL, Raff HV. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 1993;53:2560-65.
12. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci U S A 1997;94:7509-14. (Pubitemid 27345346)
13. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97:1392-8. (Pubitemid 32183764)
14. Li B, Shi S, Qian W, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008;68:2400-8. (Pubitemid 351521815)
15. Meng R, Smallshaw JE, Pop LM, et al. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res 2004;10:1274-81. (Pubitemid 38365217)
16. Liu XY, Pop LM, Roopenian DC, Ghetie V, Vitetta ES, Smallshaw JE. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. Int Immunopharmacol 2006;6:791-9.
17. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-43.
18. van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-11.
19. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949-54.
20. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71.
21. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37.